HC Wainwright Forecasts Lower Earnings for Shattuck Labs

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Shattuck Labs to a loss of $0.55 per share from a projected loss of $0.42, below the consensus estimate of a $0.48 loss. The firm maintained its Buy rating and $14 price target.
• Shattuck reported a quarterly loss of $0.14 per share, missing analyst expectations of a $0.10 loss by $0.04.
• Analyst views are mixed but lean positive: MarketBeat reports an average Buy rating and $13.70 target price, while three analysts rate the stock Strong Buy, nine Buy, and one Sell.

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Shattuck Labs in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.55) for the year, down from their prior estimate of ($0.42). HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Shattuck Labs' Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.70) EPS.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.04).

Other equities analysts also recently issued research reports about the stock. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Shattuck Labs in a research note on Thursday. Wall Street Zen cut shares of Shattuck Labs from a "hold" rating to a "sell" rating in a research note on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Shattuck Labs in a research note on Friday, September 11th. JPMorgan Chase & Co. started coverage on Shattuck Labs in a report on Friday, July 24th. They set an "overweight" rating and a $10.00 price objective for the company. Finally, Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday, July 20th. They issued an "outperform" rating and a $16.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Shattuck Labs has an average rating of "Buy" and an average target price of $13.70.

Shattuck Labs Stock Performance

STTK opened at $4.62 on Monday. Shattuck Labs has a 1 year low of $1.72 and a 1 year high of $8.33. The company's 50 day simple moving average is $6.00 and its 200 day simple moving average is $6.02. The stock has a market capitalization of $463.68 million, a PE ratio of -9.06 and a beta of 1.21.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of STTK. Wellington Management Group LLP acquired a new stake in Shattuck Labs in the 2nd quarter valued at $12,269,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Shattuck Labs during the second quarter worth about $26,025,000. The Manufacturers Life Insurance Company acquired a new position in shares of Shattuck Labs during the second quarter worth about $1,576,000. Bank of New York Mellon Corp acquired a new position in shares of Shattuck Labs during the second quarter worth about $1,516,000. Finally, BlackRock Inc. acquired a new position in shares of Shattuck Labs during the second quarter worth about $27,315,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company's research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck's pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.